Engineering & Construction
Build Your Comparison
Side-by-side financial analysisStock Comparison
APG vs HON vs CARR vs JCI vs EMR vs JPM
Revenue, margins, valuation, and 5-year total return — side by side.
Conglomerates
Construction
Construction
Industrial - Machinery
Banks - Diversified
APG vs HON vs CARR vs JCI vs EMR vs JPM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||||
|---|---|---|---|---|---|---|
| Industry | Engineering & Construction | Conglomerates | Construction | Construction | Industrial - Machinery | Banks - Diversified |
| Market Cap | $18.31B | $139.60B | $58.41B | $88.44B | $80.13B | $896.00B |
| Revenue (TTM) | $8.17B | $36.76B | $21.87B | $24.43B | $18.32B | $280.33B |
| Net Income (TTM) | $324M | $4.10B | $1.32B | $3.53B | $2.44B | $57.05B |
| Gross Margin | 29.1% | 36.9% | 24.8% | 36.6% | 52.7% | 60.0% |
| Operating Margin | 6.7% | 14.9% | 8.1% | 13.6% | 19.8% | 25.9% |
| Forward P/E | 25.0x | 21.0x | 25.0x | 29.7x | 22.0x | 14.4x |
| Total Debt | $3.29B | $34.58B | $12.67B | $11.19B | $13.76B | $942.38B |
| Cash & Equiv. | $912M | $12.49B | $1.55B | $379M | $1.54B | $343.34B |
APG vs HON vs CARR vs JCI vs EMR vs JPM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| APi Group Corporati… (APG) | 100 | 522.7 | +422.7% |
| Honeywell Internati… (HON) | 100 | 152.4 | +52.4% |
| Carrier Global Corp… (CARR) | 100 | 314.6 | +214.6% |
| Johnson Controls In… (JCI) | 100 | 424.6 | +324.6% |
| Emerson Electric Co. (EMR) | 100 | 230.6 | +130.6% |
| JPMorgan Chase & Co. (JPM) | 100 | 341.0 | +241.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: APG vs HON vs CARR vs JCI vs EMR vs JPM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
APG is the clearest fit if your priority is long-term compounding.
- 5.1% 10Y total return vs CARR's 5.2%
- 12.7% revenue growth vs CARR's -3.3%
HON has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- Dividend streak 8 yrs, beta 0.84, yield 2.1%
- Lower volatility, beta 0.84, current ratio 1.32x
- Beta 0.84, yield 2.1%, current ratio 1.32x
- Beta 0.84 vs EMR's 1.61
Among these 6 stocks, CARR doesn't own a clear edge in any measured category.
JCI is the #2 pick in this set and the best alternative if momentum and efficiency is your priority.
- +41.4% vs CARR's -2.3%
- 9.0% ROA vs JPM's 1.3%, ROIC 8.5% vs 4.5%
EMR is the clearest fit if your priority is growth exposure.
- Rev growth 3.0%, EPS growth 17.8%, 3Y rev CAGR 9.3%
JPM ranks third and is worth considering specifically for valuation efficiency.
- PEG 0.81 vs HON's 11.42
- Lower P/E (14.4x vs 22.0x), PEG 0.81 vs 4.87
- 20.4% margin vs APG's 4.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.7% revenue growth vs CARR's -3.3% | |
| Value | Lower P/E (14.4x vs 22.0x), PEG 0.81 vs 4.87 | |
| Quality / Margins | 20.4% margin vs APG's 4.0% | |
| Stability / Safety | Beta 0.84 vs EMR's 1.61 | |
| Dividends | 2.1% yield, 8-year raise streak, vs EMR's 1.5%, (1 stock pays no dividend) | |
| Momentum (1Y) | +41.4% vs CARR's -2.3% | |
| Efficiency (ROA) | 9.0% ROA vs JPM's 1.3%, ROIC 8.5% vs 4.5% |
APG vs HON vs CARR vs JCI vs EMR vs JPM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
APG vs HON vs CARR vs JCI vs EMR vs JPM — Financial Metrics
Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 2 of 6 categories
APG leads 1 • HON leads 0 • CARR leads 0 • JCI leads 0 • EMR leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 34.3x APG's $8.2B. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to APG's 4.0%. On growth, APG holds the edge at +15.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| RevenueTrailing 12 months | $8.2B | $36.8B | $21.9B | $24.4B | $18.3B | $280.3B |
| EBITDAEarnings before interest/tax | $876M | $6.5B | $3.1B | $3.9B | $4.7B | $81.4B |
| Net IncomeAfter-tax profit | $324M | $4.1B | $1.3B | $3.5B | $2.4B | $57.0B |
| Free Cash FlowCash after capex | $680M | $4.2B | $1.7B | $1.4B | $3.1B | $100.9B |
| Gross MarginGross profit ÷ Revenue | +29.1% | +36.9% | +24.8% | +36.6% | +52.7% | +60.0% |
| Operating MarginEBIT ÷ Revenue | +6.7% | +14.9% | +8.1% | +13.6% | +19.8% | +25.9% |
| Net MarginNet income ÷ Revenue | +4.0% | +11.2% | +6.0% | +14.5% | +13.3% | +20.4% |
| FCF MarginFCF ÷ Revenue | +8.3% | +11.4% | +7.6% | +5.7% | +17.0% | +36.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.3% | -6.9% | +2.4% | +8.2% | +2.9% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +61.5% | -41.9% | -40.4% | +38.9% | +28.2% | +16.0% |
Valuation Metrics
JPM leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 16.0x trailing earnings, JPM trades at a 71% valuation discount to JCI's 55.1x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs HON's 16.30x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Market CapShares × price | $18.3B | $139.6B | $58.4B | $88.4B | $80.1B | $896.0B |
| Enterprise ValueMkt cap + debt − cash | $20.7B | $161.7B | $69.5B | $99.3B | $92.3B | $1.50T |
| Trailing P/EPrice ÷ TTM EPS | -61.36x | 29.93x | 41.12x | 55.12x | 35.41x | 16.00x |
| Forward P/EPrice ÷ next-FY EPS est. | 24.96x | 20.96x | 24.96x | 29.66x | 21.99x | 14.40x |
| PEG RatioP/E ÷ EPS growth rate | — | 16.30x | — | 2.15x | 7.84x | 0.90x |
| EV / EBITDAEnterprise value multiple | 23.48x | 20.33x | 22.46x | 26.88x | 18.29x | 18.36x |
| Price / SalesMarket cap ÷ Revenue | 2.31x | 3.73x | 2.69x | 3.75x | 4.45x | 3.20x |
| Price / BookPrice ÷ Book value/share | 5.17x | 9.17x | 4.19x | 7.32x | 3.99x | 2.47x |
| Price / FCFMarket cap ÷ FCF | 27.62x | 25.89x | 34.42x | 91.65x | 30.05x | 8.88x |
Profitability & Efficiency
Evenly matched — APG and JCI each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
JCI delivers a 24.9% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $9 for CARR. EMR carries lower financial leverage with a 0.68x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), APG scores 8/9 vs CARR's 4/9, reflecting strong financial health.
| Metric | ||||||
|---|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.7% | +23.1% | +9.1% | +24.9% | +12.1% | +15.9% |
| ROA (TTM)Return on assets | +3.7% | +5.3% | +3.5% | +9.0% | +5.8% | +1.3% |
| ROICReturn on invested capital | +7.4% | +12.6% | +6.7% | +8.5% | +8.2% | +4.5% |
| ROCEReturn on capital employed | +8.5% | +12.6% | +7.2% | +9.8% | +10.0% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 6 | 4 | 6 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.96x | 2.24x | 0.90x | 0.86x | 0.68x | 2.60x |
| Net DebtTotal debt minus cash | $2.4B | $22.1B | $11.1B | $10.8B | $12.2B | $599.0B |
| Cash & Equiv.Liquid assets | $912M | $12.5B | $1.6B | $379M | $1.5B | $343.3B |
| Total DebtShort + long-term debt | $3.3B | $34.6B | $12.7B | $11.2B | $13.8B | $942.4B |
| Interest CoverageEBIT ÷ Interest expense | 6.08x | 3.92x | 5.76x | 18.41x | 6.46x | 0.74x |
Total Returns (Dividends Reinvested)
APG leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in APG five years ago would be worth $28,744 today (with dividends reinvested), compared to $10,790 for HON. Over the past 12 months, JCI leads with a +41.4% total return vs CARR's -2.3%. The 3-year compound annual growth rate (CAGR) favors APG at 36.2% vs HON's 5.5% — a key indicator of consistent wealth creation.
| Metric | ||||||
|---|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +8.6% | +13.7% | +31.5% | +18.8% | +6.2% | -0.5% |
| 1-Year ReturnPast 12 months | +31.7% | -0.5% | -2.3% | +41.4% | +14.6% | +21.8% |
| 3-Year ReturnCumulative with dividends | +152.5% | +17.5% | +58.0% | +135.2% | +77.8% | +138.2% |
| 5-Year ReturnCumulative with dividends | +187.4% | +7.9% | +59.3% | +129.9% | +57.7% | +118.2% |
| 10-Year ReturnCumulative with dividends | +511.0% | +135.6% | +516.9% | +299.1% | +216.5% | +465.8% |
| CAGR (3Y)Annualised 3-year return | +36.2% | +5.5% | +16.5% | +33.0% | +21.1% | +33.6% |
Risk & Volatility
Evenly matched — HON and JCI each lead in 1 of 2 comparable metrics.
Risk & Volatility
HON is the less volatile stock with a 0.84 beta — it tends to amplify market swings less than EMR's 1.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JCI currently trades 97.2% from its 52-week high vs APG's 84.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.26x | 0.84x | 1.27x | 1.01x | 1.61x | 0.94x |
| 52-Week HighHighest price in past year | $49.99 | $248.18 | $81.09 | $149.10 | $165.15 | $337.25 |
| 52-Week LowLowest price in past year | $31.75 | $186.76 | $50.24 | $100.86 | $122.64 | $262.71 |
| % of 52W HighCurrent price vs 52-week peak | +84.7% | +88.8% | +86.2% | +97.2% | +86.6% | +95.1% |
| RSI (14)Momentum oscillator 0–100 | 49.6 | 48.4 | 60.1 | 53.6 | 53.9 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 2.5M | 4.1M | 6.2M | 3.2M | 2.5M | 7.0M |
Analyst Outlook
Evenly matched — HON and EMR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: APG as "Buy", HON as "Buy", CARR as "Buy", JCI as "Buy", EMR as "Buy", JPM as "Buy". Consensus price targets imply 24.0% upside for APG (target: $53) vs -1.5% for CARR (target: $69). For income investors, HON offers the higher dividend yield at 2.10% vs JCI's 1.03%.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $52.50 | $250.08 | $68.86 | $156.40 | $163.62 | $339.75 |
| # AnalystsCovering analysts | 8 | 28 | 26 | 45 | 41 | 61 |
| Dividend YieldAnnual dividend ÷ price | — | +2.1% | +1.3% | +1.0% | +1.5% | +1.9% |
| Dividend StreakConsecutive years of raises | 0 | 8 | 0 | 5 | 54 | 15 |
| Dividend / ShareAnnual DPS | — | $4.63 | $0.91 | $1.49 | $2.10 | $5.95 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.4% | +2.7% | +5.0% | +6.8% | +1.6% | +3.9% |
JPM leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). APG leads in 1 (Total Returns). 3 tied.
APG vs HON vs CARR vs JCI vs EMR vs JPM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is APG or HON or CARR or JCI or EMR or JPM a better buy right now?
For growth investors, APi Group Corporation (APG) is the stronger pick with 12.
7% revenue growth year-over-year, versus -3. 3% for Carrier Global Corporation (CARR). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate APi Group Corporation (APG) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — APG or HON or CARR or JCI or EMR or JPM?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 16. 0x versus Johnson Controls International plc at 55. 1x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Honeywell International Inc. 's 11. 42x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — APG or HON or CARR or JCI or EMR or JPM?
Over the past 5 years, APi Group Corporation (APG) delivered a total return of +187.
4%, compared to +7. 9% for Honeywell International Inc. (HON). Over 10 years, the gap is even starker: CARR returned +516. 9% versus HON's +135. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — APG or HON or CARR or JCI or EMR or JPM?
By beta (market sensitivity over 5 years), Honeywell International Inc.
(HON) is the lower-risk stock at 0. 84β versus Emerson Electric Co. 's 1. 61β — meaning EMR is approximately 93% more volatile than HON relative to the S&P 500. On balance sheet safety, Emerson Electric Co. (EMR) carries a lower debt/equity ratio of 68% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — APG or HON or CARR or JCI or EMR or JPM?
By revenue growth (latest reported year), APi Group Corporation (APG) is pulling ahead at 12.
7% versus -3. 3% for Carrier Global Corporation (CARR). On earnings-per-share growth, the picture is similar: Emerson Electric Co. grew EPS 17. 8% year-over-year, compared to -72. 4% for Carrier Global Corporation. Over a 3-year CAGR, EMR leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — APG or HON or CARR or JCI or EMR or JPM?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus 3. 8% for APi Group Corporation — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 7. 0% for APG. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is APG or HON or CARR or JCI or EMR or JPM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Honeywell International Inc. 's 11. 42x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 29. 7x for Johnson Controls International plc — 15. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for APG: 24. 0% to $52. 50.
08Which pays a better dividend — APG or HON or CARR or JCI or EMR or JPM?
In this comparison, HON (2.
1% yield), JPM (1. 9% yield), EMR (1. 5% yield), CARR (1. 3% yield), JCI (1. 0% yield) pay a dividend. APG does not pay a meaningful dividend and should not be held primarily for income.
09Is APG or HON or CARR or JCI or EMR or JPM better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Emerson Electric Co. (EMR) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, EMR: +216. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between APG and HON and CARR and JCI and EMR and JPM?
These companies operate in different sectors (APG (Industrials) and HON (Industrials) and CARR (Industrials) and JCI (Industrials) and EMR (Industrials) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: APG is a mid-cap quality compounder stock; HON is a mid-cap quality compounder stock; CARR is a mid-cap quality compounder stock; JCI is a mid-cap quality compounder stock; EMR is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. HON, CARR, JCI, EMR, JPM pay a dividend while APG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.